EMA Authorised: Mysimba (bupropion hydrochloride;naltrexone hydrochloride) — Orexigen Therapeutics Ireland Limited

View source ↗

Summary

The EMA authorised Mysimba, a fixed-dose combination of bupropion hydrochloride and naltrexone hydrochloride, for obesity and overweight. Orexigen Therapeutics …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity
• Overweight

Drugs mentioned

• Mysimba (naltrexone/bupropion)

Snippet

Status: Authorised. Therapeutic area: Obesity;Overweight. MAH: Orexigen Therapeutics Ireland Limited. Decision date: 17/02/2026